4.6 Article

Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination

Journal

VIRUSES-BASEL
Volume 15, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/v15030627

Keywords

SARS-CoV-2; memory B-cells; cross-reactive; coronavirus; mRNA vaccine

Categories

Ask authors/readers for more resources

This study investigated the impact of SARS-CoV-2 mRNA-based vaccination on T-cell responses and specific memory B-cells (MBCs) in relation to subsequent infections. It was found that in unexposed individuals, most individuals with T-cell cross-reactivity showed T-cell responses to the spike protein after vaccination. However, T-cell cross-reactivity did not increase the levels of specific MBCs in unexposed individuals. The study also found that the level of specific MBCs determined the time to breakthrough infections, regardless of T-cell cross-reactivity.
Objective: T-cell responses against SARS-CoV-2 are observed in unexposed individuals, attributed to previous common human coronavirus (HCoV) infections. We evaluated the evolution of this T-cell cross-reactive response and the specific memory B-cells (MBCs) after the SARS-CoV-2 mRNA-based vaccination and its impact on incident SARS-CoV-2 infections. Methods: This was a longitudinal study of 149 healthcare workers (HCWs) that included 85 unexposed individuals that were subdivided according to previous T-cell cross-reactivity, who were compared to 64 convalescent HCWs. Changes in specific T-cell response and memory B-cell (MBC) levels were compared at baseline and after two doses of the SARS-CoV-2 mRNA-based vaccine. Results: A cross-reactive T-cell response was found in 59% of unexposed individuals before vaccination. Antibodies against HKU1 positively correlated with OC43 and 229E antibodies. Spike-specific MBCs was scarce in unexposed HCWs regardless of the presence of baseline T-cell cross-reactivity. After vaccination, 92% and 96% of unexposed HCWs with cross-reactive T-cells had CD4+ and CD8+ T-cell responses to the spike protein, respectively. Similar results to that were found in convalescents (83% and 92%, respectively). Contrarily, higher than that which was observed in unexposed individuals without T-cell cross-reactivity showed lower CD4+ and CD8+ T-cell responses (73% in both cases, p = 0.03). Nevertheless, previous cross-reactive T-cell response was not associated with higher levels of MBCs after vaccination in unexposed HCWs. During a follow-up of 434 days (IQR, 339-495) after vaccination, 49 HCWs (33%) became infected, with a significant positive correlation between spike-specific MBC levels and isotypes IgG+ and IgA+ after vaccination and a longer time to get infected. Interestingly, T-cell cross-reactivity did not reduce the time to vaccine breakthrough infections. Conclusion: While pre-existing T-cell cross-reactivity enhances the T-cell response after vaccination, it does not increase SARS-CoV-2-specific MBC levels in the absence of previous infection. Overall, the level of specific MBCs determines the time to breakthrough infections, regardless of the presence of T-cell cross-reactivity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Virology

Expansion of CD56dimCD16neg NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients

Jose L. Casado, Elisa Moraga, Pilar Vizcarra, Hector Velasco, Adrian Martin-Hondarza, Johannes Haemmerle, Sandra Gomez, Carmen Quereda, Alejandro Vallejo

Summary: Infection with SARS-CoV-2 leads to increased levels of inflammatory cytokines and alterations in the distribution and phenotype of NK cells, which may enhance the impairment of the crucial innate defense during COVID-19 infection.

VIRUSES-BASEL (2022)

Article Microbiology

Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity

Alejandro Vallejo, Adrian Martin-Hondarza, Sandra Gomez, Hector Velasco, Pilar Vizcarra, Johannes Haemmerle, Jose L. Casado

Summary: SARS-CoV-2 spike mRNA vaccines not only induce specific responses to the spike protein, but also enhance T-cell responses to the membrane and nucleocapsid proteins. This suggests that mRNA vaccines serve as broad boosters of cellular responses and provide extended protection against viral variants.

FRONTIERS IN MICROBIOLOGY (2022)

Article Infectious Diseases

Low risk of bacterial co-infection, opportunistic diseases, and persistent immunosuppression in people living with HIV and COVID-19

Jose L. Casado, Pilar Vizcarra, Maria J. Vivancos, Javier Martinez-Sanz, Maria J. Perez-Elias, Ana Moreno, Alejandro Vallejo

Summary: This study investigated the co-infection and superinfection rates, as well as the changes in CD4+ count and CD4+/CD8+ ratio, in hospitalized people living with HIV (PLWH) with COVID-19. The results showed that bacterial co-infection was not frequent and most patients experienced immune recovery after the disease.

INFECTION (2022)

Article Medicine, General & Internal

Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination

Jose L. Casado, Johannes Haemmerle, Pilar Vizcarra, Gema Ramirez-Alonso, Andrea Salazar-Tosco, Beatriz Romero-Hernandez, Magdalena Blasco, Mario Rodriguez-Dominguez, Itria G. Mirabella, Alejandro Vallejo, Marina Fernandez-Escribano

Summary: The risk of SARS-CoV-2 reinfection is closely related to the clinical and serological presentation of COVID-19. COVID-19 vaccination further decreases the risk of reinfection, especially among seropositive individuals.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Immunology

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2

Jose L. Casado, Pilar Vizcarra, Johannes Haemmerle, Hector Velasco, Adrian Martin-Hondarza, Mario J. Rodriguez-Dominguez, Tamara Velasco, Sara Martin, Beatriz Romero-Hernandez, Marina Fernandez-Escribano, Alejandro Vallejo

Summary: Little is known about the factors associated with the lack of T-cell response to mRNA vaccines against SARS-CoV-2. A study on a cohort of 61 healthcare workers found that 21% and 16% showed a lack of CD4+ and CD8+ T-cell response after the first dose of the mRNA BNT162b vaccine, and 12% and 7% showed a lack of response after the second dose, respectively. Pre-existing T-cell immunity, either from past infection or cross-reactive cellular response, was significantly associated with T-cell response frequency and magnitude. Baseline CD4+ T-cell levels correlated positively with the titer of specific IgG antibodies. These findings suggest that cross-reactive T-cells are linked to better cellular and humoral responses after mRNA vaccination.

VACCINE: X (2022)

Article Infectious Diseases

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Matilde Sanchez-Conde, Pilar Vizcarra, Jose Manuel Perez-Garcia, Maria Gion, Maria Pilar Martialay, Javier Taboada, Alberto Alonso-Fernandez, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De la Torre, Antonio Llombart-Cussac, Javier Cortes

Summary: The study evaluated the efficacy and safety of Pembrolizumab and tocilizumab in hospitalized COVID-19 pneumonia patients at high risk without mechanical ventilation. The results showed that adding Pembrolizumab and tocilizumab to the treatment regimen reduced the hospitalization period, resulted in faster discharges, and had no adverse effects.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Article Public, Environmental & Occupational Health

Improving Recognition of Fracture Risk in People with Human Immunodeficiency Virus: Performance and Model Contribution of Two Common Risk Assessment Tools

Pilar Vizcarra, Ana Moreno, Maria J. Vivancos, Alfonso Muriel Garcia, Ricardo Pelazas Gonzalez, Felix Gutierrez, Diana Corona Mata, Pepa Galindo, Sonia Calzado, Jose L. Casado

Summary: The study evaluated the performance of FRAX and QFracture scoring systems in predicting fragility fractures in HIV patients. The results showed that both tools displayed acceptable discrimination, but significantly underestimated the risk of fragility fractures. The recommended assessment thresholds were not suitable for this population as they failed to identify individuals with fragility fractures during follow-up.

AIDS PATIENT CARE AND STDS (2023)

Article Infectious Diseases

Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis

Rosa Escudero-Sanchez, Elena Rubio Martin, Pilar Vizcarra, Francisco Braojos Sanchez, Alvaro Diaz Gago, Laura Del Campo Albendea, Alfonso Muriel, Ana Halperin, Manuel Ponce Alonso, Santiago Moreno Guillen, Javier Cobo

Summary: In this study, the recurrence rate of Clostridioides difficile infection (CDI) was compared between conventional dosing of fidaxomicin (FCD) and extended-pulsed dosing of fidaxomicin (FEPD). The results showed no significant difference in the recurrence rate between the two dosing regimens. Further clinical trials or large observational studies are needed to compare the efficacy of these two dosing regimens.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Editorial Material Virology

Concluding Remarks for Special Issue HTLV-HIV Co-Infections

Alejandro Vallejo, Maria Abad-Fernandez

VIRUSES-BASEL (2023)

Article Oncology

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors

Cristina Saavedra, Alejandro Vallejo, Federico Longo, Juan Jose Serrano, Maria Fernandez, Maria Gion, Elena Lopez-Miranda, Noelia Martinez-Janez, Eva Guerra, Jesus Chamorro, Diana Rosero, Hector Velasco, Adrian Martin, Alfredo Carrato, Jose Luis Casado, Alfonso Cortes

Summary: Limited data on the immune response to mRNA SARS-CoV-2 vaccines in breast cancer patients receiving CDK4/6 inhibitors are available. In this study, a comparison was made between breast cancer patients receiving CDK4/6 inhibitors and healthcare workers after mRNA-1273 vaccination. The results showed a stronger humoral response but a reduced trend in T-cell response in women receiving CDK4/6 inhibitors.

CANCERS (2023)

Article Endocrinology & Metabolism

A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model

Pilar Vizcarra, Ana Moreno, Maria J. Vivancos, Alfonso Muriel Garcia, Margarita Ramirez Schacke, Juan Gonzalez-Garcia, Adrian Curran, Rosario Palacios, Antonio Jesus Sanchez Guirao, Sergio Reus Banuls, Santiago Moreno Guillen, Jose L. Casado, Spanish HIV Res Network CoRIS

Summary: This study aimed to develop a model for predicting the long-term risk of fragility fractures in people with HIV. The model accurately predicted the 5- and 10-year risk of fragility fractures and showed better performance compared to the existing prediction tool.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Article Infectious Diseases

Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort

Carmen Hidalgo-Tenorio, Ines Pitto-Robles, Daniel Arnes Garcia, F. Javier Membrillo de Novales, Laura Morata, Raul Mendez, Olga Bravo de Pablo, Vicente Abril Lopez de Medrano, Miguel Salavert Lleti, Pilar Vizcarra, Jaime Lora-Tamayo, Ana Arnaiz Garcia, Leonor Moreno Nunez, Mar Masia, Maria Pilar Ruiz Seco, Svetlana Sadyrbaeva-Dolgova

Summary: This study analyzed the use of ceftobiprole medocaril (Cefto-M) in Spanish clinical practice, primarily for respiratory and skin and soft tissue infections, as rescue therapy in severe infectious diseases. Age, ICU admission, and sepsis/septic shock were identified as factors associated with higher mortality rates.

ANTIBIOTICS-BASEL (2023)

No Data Available